March 22, 2019

Seikagaku Launches HyLink®, an Intra-Articular Single-Injection
Viscosupplement for the Treatment of Knee Osteoarthritis in Italy
Seikagaku Corporation (Tokyo, Japan; “Seikagaku”) announced today the launch of HyLink®, anintra-articular single-injection viscosupplement for the treatment of knee osteoarthritis in Italy on
March 21, 2019 (local time) through MDM S.p.A. (Lombardia, Italy; “MDM”).
HyLink®, a CE marked medical device (obtained in June 2018) is an intra-articular single-injection
viscosupplement for the treatment of knee osteoarthritis. Its main ingredient, a cross-linked
hyaluronate hydrogel made by Seikagaku’s unique technology, stays long in the knee joint cavity
and provides pain relief for 26 weeks.
MDM is a pharmaceutical company with its strengths in the fields of neurology and orthopedics
and a nationwide sales network in Italy. MDM entered into an exclusive distributorship agreementwith Seikagaku in 2003 and sells the intra-articular multiple-injection viscosupplement for thetreatment of knee osteoarthritis SUPARTZ®. Since the Italian market for hyaluronic acid treatments
continues to grow steadily with the expansion of the elderly population, MDM will aim to further
strengthen its presence in the market by newly introducing HyLink® in addition to SUPARTZ®.
Seikagaku will continue to support MDM’s sales promotion activities through the provision ofacademic information in its capacity as a manufacturer, and Seikagaku and MDM together willcontribute to improving the quality of life of patients.
*CE mark: A mark that certifies that products meet safety standards at the time of export to EU
member countriesHyLink®

Knee Osteoarthritis
Knee osteoarthritis is a disease in which joint tissue degenerates and inflammation and pain occur
due to the wearing of articular cartilage. Since bones come into direct contact with one another as
the condition and cartilage wear progress, intense pain occurs when the knee joint is moved. The
occurrence of knee osteoarthritis is said to be associated with aging, obesity, external injury,

1excessive exercise, genetic predisposition, and other factors.
About Seikagaku Corporation
Seikagaku Corporation is an R&D-oriented pharmaceutical company that focuses on glycoscience
as an area of specialization. Since its foundation in 1947, Seikagaku has continuously focused on
the possibilities of glycoscience and developed original, beneficial pharmaceutical products andmedical devices in the fields of orthopedic disorders and ophthalmic diseases. Under a uniquebusiness model of specializing in R&D and manufacturing without having an in-house
pharmaceuticals sales division, Seikagaku contributes to healthy and fulfilling lives for people aroundthe world by marketing products globally in collaboration with companies having strengths inparticular countries and product areas. Detailed information is available on the Seikagaku website(www.seikagaku.co.jp/english/).
About MDM
MDM is a pharmaceutical company founded in 1971 that has a nationwide sales network in Italy andoffers innovative products. It has expertise and strengths particularly in sales of products in the fieldsof neurology and orthopedics. Detailed information is available on the MDM website(www.mdmspa.com).

< Cautionary Notes >This press release contains forward-looking statements regarding future management
strategies or performance forecasts. These descriptions are based on judgments derived frominformation that is currently available to Seikagaku and are subject to risk and uncertainty.
Actual results and developments may differ significantly from these descriptions due to various
factors.
Information about pharmaceutical products or medical devices (including products currently indevelopment) contained in this press release is not intended to constitute an advertisement ormedical advice.

#######

2